[1] 安利,朱琳.血栓性血小板减少性紫癜12例临床分析[J].血栓与止血,2016, 22(3):318-320. [2] 中华医学会血液学分会血栓与止血组.血栓性血小板减少性紫癜诊断与治疗中国专家共识(2012年版)[J].中华医学会血液学分会血栓与止血组,2012,33(11):983-984. [3] Sadlen J E, Muia J, Dolatshahi L, et al. Efficacy of adjuvant low dose rituximab and plasma exchange for acquired TTP with severe ADAMTS13 deficiency-results of the ART study[J].Blood,2018,132(Suppl 1):374. [4] 李柏成,张剑锋. 血栓性血小板减少性紫癜并肺栓塞1例[J].中华灾害救援医学, 2019,7(1):50-52. [5] 刘蕾,马壮,张云,等.静脉血栓栓塞症患者易栓症的临床研究[J].临床肺科杂志,2018,23(3):456-458. [6] 邓明扬.血栓性血小板减少性紫癜临床与实验室特点分析及动静脉血栓形成获得性/遗传性危险因素筛查[D].长沙:中南大学, 2010. [7] 徐焕铭,樊华.血栓性血小板减少性紫癜诊治现状及展望[J].中国实用内科杂志,2017,37(2):99-103. [8] 辛鹏亮,李纯团,刘德斌,等.继发性血栓性血小板减少性紫癜17例临床分析[J].血栓与止血学,2014,20(5):235-238. [9] Matsumoto M, Yagi H,Ishizashi H, et al. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome[J]. Semin Hematol, 2004,41(1):68-74. [10] Matsumoto M, Fujimura Y, Wada H, et al.Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan[J].Int J Hematol,2017,106(1):3-15. [11] Jamme M,Rondeau E.The PLASMIC score for thrombotic thrombocytopenic purpura[J].Lancet Haematol,2017,4(4):e148-e149. [12] Sayani F A, Abrams C S. How I treat refractory thrombotic thrombocyto-penic purpura[J].Blood,2015,125(25):3860-3867. [13] Cuker A. Adjuvant rituximab to prevent TTP relapse[J].Blood,2016, 127(24):2952-2953. |